Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 60Lymphoma 56Leukemia, Myeloid, Acute 51Leukemia 50Lymphoma, Non-Hodgkin 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Hodgkin Disease 36Myelodysplastic Syndromes 28Lymphoma, Large B-Cell, Diffuse 27Breast Neoplasms 24Lymphoma, Mantle-Cell 23Neuroblastoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Burkitt Lymphoma 17Lymphoma, Follicular 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Central Nervous System Neoplasms 13Lymphoma, Large-Cell, Immunoblastic 12Sarcoma 11Neoplasms, Plasma Cell 11Brain Neoplasms 11Recurrence 10Lymphoma, B-Cell, Marginal Zone 10Neoplasms 9Hematologic Neoplasms 9Congenital Abnormalities 9Myeloproliferative Disorders 8Leukemia, Myelomonocytic, Chronic 8Leukemia, Biphenotypic, Acute 8Graft vs Host Disease 8

Interventions

plerixafor 1ofatumumab 1Panzyga 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Agammaglobulinemia × Granulocyte Colony-Stimulating Factor × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡